Fig. 6: HER2 Heterogeneity scores derived from clustering analysis reveal correlation to clinical outcome. | npj Breast Cancer

Fig. 6: HER2 Heterogeneity scores derived from clustering analysis reveal correlation to clinical outcome.

From: Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

Fig. 6

Following the selection of qualified ER, PR, HER2, AR, and p53 CyCIF antibodies, the expression of selected antibodies was evaluated at a single-cell level in 567 HER2+ invasive breast cancer samples, representing 189 patients. Tissues from HER2+ patients (n = 77) in which there were at least 500 cells pooled from the triplicate cores were used for ITH analysis. a HER2 expression was analyzed in single cells, and the coefficient of variation (C.V.) among patients was plotted (y axis) by recurrence status. b HER2 and Ki67 mean intensity expression measured by CyCIF. c Distribution of cells across all clusters (blue) and HER2 core number 113 (orange) and d representative tumor with low (HER2-5 and HER2-161) and high (HER2-164 and HER2-170) heterogeneity. e HER2 heterogeneity scores were generated by identifying cells from each tissue mapped to the entire t-SNE. A larger boundary corresponds with higher diversity. f Samples that have equal distribution of each cluster have high heterogeneity and are diamond-shaped in the boundary mapping. g GMM and t-SNE scores reveal an association with recurrence. h Patients treated with Trastuzumab were removed from the GMM and t-SNE score analysis.

Back to article page